NEW YORK (GenomeWeb News) – A new center in Ontario, Canada focused on pharmacogenetic applications for addiction and mental health has been established with a C$19 million (US$19.1 million) investment.
NEW YORK (GenomeWeb News) – San Diego-based Ridge Diagnostics today said that it has licensed exclusive rights to Ameritox to its MDDScore, a multiplex biomarker test for major depressive disorder.
NEW YORK (GenomeWeb News) – The Massachusetts General Hospital is starting a major study aimed at guiding treatment of patients suffering from treatment-resistant major depressive disorder.
This story originally ran on Nov. 4.
Myriad Genetics has eight protein-based tests progressing toward commercialization, company officials said this week on a conference call discussing the firm's earnings for the quarter ended Sept. 30.
With the deal, Myriad will acquire RBM's biomarker discovery platform as well as its pipeline of proprietary protein biomarker-based diagnostics, including two tests that a Myriad official said were "relatively close to commercial launch."
WSU and the Michigan Technology and Research Institute are seeking funding to form a company to shepherd to clinical trials WSU's first candidate, a triple uptake inhibitor for treating depression. They eventually hope to attract a pharma partner for further development.
The publisher of the Science family of journals will allow some authors to place peer-reviewed versions of their papers into publicly accessible repositories.
